Open

Ruxolitinib in Patients with High Risk and Premalignant Breast Conditions

To determine the difference in change in apoptosis between diagnosis and surgery as a function of ruxolitinib treatment versus placebo, among participants with high-risk or premalignant breast conditions.

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Visit Availability

Standard business hours (M-F, 8-5)
Visits can be combined with regular clinical appointments

Location

North Carolina (Statewide)

What will be asked of you

The study involves blood draws, physical exam, receipt of study drug or placebo, and anticipated surgery after study treatment. You will meet with a member of the study team in addition to your oncology care team during your visits.

Incentives

Study medication.

In-person visits:
5

Total length of participation:
About 7 weeks per the consent

Looking for Specific Volunteers

Able to participate:

You have been diagnosed with a precancerous breast condition from a biopsy

Not eligible if:

You are pregnant or nursing
You are currently receiving another research study drug
You have a current or previous history of invasive breast cancer
You have been diagnosed with having Hepatitis B or C
You have been diagnosed with HIV and are receiving antiretroviral therapy

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Lineberger Clinical Research
cancerclinicaltrials@med.unc.edu
(919) 966-4432

Primary Visit Location

UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Kristalyn Gallagher
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Breast)

IRB Number

19-0116

ClinicalTrials.gov

NCT02928978

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.